Daily20h
GSK Ojjaara approved in Canada for treatment of myelofibrosis in adults who have moderate to severe anemia
Mississauga: GSK has announced that Health Canada has approved Ojjaara (momelotinib) for the treatment of splenomegaly and/or ...
Pharmabiz1d
Health Canada approves GSK’s Ojjaara for the treatment of myelofibrosis in adults who have moderate to severe anaemia
Mississauga, Ontario Thursday, November 14, 2024, 09:00 Hrs [IST] ...
Pharmaceutical Technology1d
Health Canada approves GSK’s Ojjaara for myelofibrosis in anaemia patients
GSK added Ojjaara to its portfolio through the acquisition of Sierra in 2022. Credit: Magda Wygralak via Shutterstock. Health ...
Ojjaara (momelotinib) approved in Canada for the treatment of myelofibrosis in adults who have moderate to severe anemia
CNW/ - GSK announced today that Health Canada has approved Ojjaara (momelotinib) for the treatment of splenomegaly and/or ...
Too Old to Operate6d
Navigating Challenges in HSCT Eligibility for Myelofibrosis
Updated guidelines on allogeneic hematopoietic stem cell transplantation for myelofibrosis examine spleen-related ...
Strategic Clinical Advances and Revenue Growth Drive Buy Rating for Karyopharm Therapeutics
Robert W. Baird analyst Colleen M. Kusy maintained a Buy rating on Karyopharm Therapeutics (KPTI – Research Report) on November 6 and set ...
BioPharma Dive6d
Tezspire succeeds in chronic rhinosinusitis; Gilead writes down Trodelvy value
AstraZeneca and Amgen's drug could have a new use after positive Phase 3 study results. Elsewhere, Jazz set new plans for a ...
Promising Growth Potential for Keros Therapeutics Driven by Robust Clinical Pipeline and Upcoming Data Releases
Leerink Partners analyst Thomas Smith has reiterated their bullish stance on KROS stock, giving a Buy rating yesterday. Thomas Smith’s ...